Seeking Alpha

Seeking Alpha Portfolio App for iPad

5,637 people get AMGN articles and Market Currents by email alert.

Get email alerts on AMGN »

AMGN

Amgen Inc.

5/24/2013, 11:58 AM ET

Quote & Headlines Market Currents StockTalk

All
| Earnings
| Dividends
| M&A
| On the move

Thursday, May 16, 1:49 PM Biotech names are weak today on the back of several ASCO data presentation releases: REGN -2.3%, ALXN -4.2%, VRTX -2.3%, CELG -4.5%, ARRY -2.2%, AMGN -1.4%. 1 Comment [Healthcare, On the Move]
Monday, May 6, 1:36 PM Merck (MRK -1.3%) gets no love today from the FDA's approval of Liptruxet late Friday, as the stock is likely dragged down with the rest of the big pharma names on the back of a CNBC report that criticizes their earnings so far. The article points to the fact that pharmaceutical companies have seen a 4.7% contraction in earnings, and a 3.2% drop in revenue this quarter. Why? Morningstar's Damien Cover says there are two primary reasons: FX impact, especially from the yen, and intensified generic competition from patent losses. Comment! [Healthcare, On the Move]
Monday, May 6, 7:33 AM Transgenomic (TBIO.OB) enters into a collaborative agreement with Amgen (AMGN) for the further development of a CE-IVD test for the detection of RAS mutations in patients with metastatic colorectal cancer. (PR) Comment! [Healthcare]
Friday, May 3, 5:43 PM An FDA panel has voted 17-1 that Amgen's (AMGN) blood-boosting drugs would benefit radiation survivors in the event of a nuclear attack. The drugs, known as Leukocyte growth factor drugs, are normally given to cancer patients to combat the effects of chemotherapy. The panel observed monkeys exposed to radiation, and those given AMGN's Neupogen showed a greater likelihood of survival, and the FDA says it's likely to provide the same benefit to people as well. Comment! [Healthcare]
Friday, May 3, 4:18 PM By a 17-1 margin, the FDA votes Amgen's (AMGN +0.8%) Neulasta and Neupogen drugs could improve survival rates for people exposed to radiation following a nuclear attack. Bloomberg recently observed Neulasta and Neupogen , which are used to prevent infection during chemotherapy, collectively produced ~$5.4B in 2012 sales for Amgen. Comment! [Healthcare]
Wednesday, May 1, 7:51 AM Goldman adds Amgen (AMGN) to its coveted Conviction Buy list saying investors have already factored in Q4 and H2 2015 patent expirations for some of the company's "key biologic franchises." Furthermore, AMGN's pipeline and "own biosimilars will allow it to replace the potential revenue that could be lost to competition." Shares +2% premarket. Comment! [Healthcare, On the Move]
Wednesday, April 24, 12:56 PM Amgen (AMGN -5.8%) slides after posting a mixed Q1 report late yesterday, beating on its EPS but coming up short on earnings. Net profit rose 21% Y/Y, due largely to a significantly lower tax rate, but the better number fails to mask disappointing sales, especially of its key arthritis drug Enbrel. The drug saw sales rise 11%, but fell short of analysts expectations. Piper Jafray cut the shares to Neutral on the report, saying the stock has limited upside until late stage clinical catalysts provide visibility into future growth. Comment! [Healthcare, Earnings, On the Move]
Tuesday, April 23, 4:04 PM Amgen (AMGN): Q1 EPS of $1.96 beats by $0.12. Revenue of $4.238B (+5% Y/Y) misses by $0.14B. Shares +0.3% AH. (PR) 2 Comments [Breaking News, Earnings, Healthcare]
Tuesday, April 23, 12:10 AM Notable earnings after Tuesday’s close: AAPL, ACC, AMGN, AWAY, BCR, BRCM, CREE, DV, EW, FBC, FTI, HA, HBI, HLIT, HTS, IRBT, ITC, JNPR, LIFE, NBR, NFX, NSC, OI, OII, OMI, PACB, PLCM, PNRA, RFMD, RHI, T, UIS, USNA, VMW, WRB, YUM, ZIXI Comment! [Earnings]
Monday, April 22, 5:35 PM Notable earnings after Tuesday’s close: AAPL, ACC, AMGN, AWAY, BCR, BRCM, CREE, DV, EW, FBC, FTI, HA, HBI, HLIT, HTS, IRBT, ITC, JNPR, LIFE, NBR, NFX, NSC, OI, OII, OMI, PACB, PLCM, PNRA, RFMD, RHI, T, UIS, USNA, VMW, WRB, YUM, ZIXI Comment! [Earnings]
Tuesday, April 16, 5:48 PM Amgen (AMGN) has agreed to to pay $24.9M to settle allegations that it violated the False Claims Act by paying kickbacks to long-term care pharmacy providers to entice them to use its Aranesp anemia drug instead of a rival medicine. The DoJ claims the payments were made to Omnicare (OCR), PharMerica (PMC) and Kindred Healthcare (KND) in return for implementing "therapeutic interchange" programs that were designed to switch Medicare and Medicaid beneficiaries from a competitor drug to AMGN's Aranesp. Comment! [Healthcare]
Thursday, March 28, 4:24 PM Biotech ETFs close at or near all-time highs as heavyweights Amgen (AMGN +2.4%), Biogen (BIIB +5.2%), Celgene (CELG +2.4%) and Gilead Sciences (GILD +2.5%) make new 52-week highs going into the holiday weekend. 1 Comment [Healthcare]
Wednesday, March 27, 3:08 PM Amgen (AMGN +1%) and Johnson & Johnson (JNJ +0.5%) also hit new 52-week highs today on the back of developments stemming from Kinmed and PFE's non-exclusive partnership. Comment! [Healthcare]
Wednesday, March 20, 8:31 AM Amgen's (AMGN) TVEC meets its primary endpoint in a Phase III trial by significantly reducing tumors in 16% of melanoma patients for at least six months vs only 2% in a control group. However, Amgen says its too early to say if TVEC helps patients live longer and if it will file for regulatory approval based on the results of the study. TVEC is a herpes simplex virus that Amgen has modified to kill cancer cells. (PR) Comment! [Healthcare]
Wednesday, March 6, 5:27 PM Amgen, Inc. (AMGN) declares $0.47/share quarterly dividend, in line with previous. Forward yield 2.02%. For shareholders of record May 16. Payable June 07. Ex-div date May 14. (PR) Comment! [Dividends]
Sunday, March 3, 4:02 AM Celgene's (CELG) Apremilast anti-inflammatory treatment reduced the symptoms of psoriasis, an autoimmune skin disease, by 75% in a third of patients in a Phase III trial. However, that's below the 41% rate in a Phase II study, raising doubts about whether Apremilast will meet Celgene's hopes and become a new blockbuster drug. Apremilast would compete with rival medicines from AbbVie (ABBV) and Amgen (AMGN). (PR) Comment! [Healthcare]

1
2
3
4
5
6
...
12
Next Page